YOLFTbeta
04

iNtRON Biotechnology Inc

048530 · KQ · Healthcare / Biotechnology

2,565.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close2,565.00
Open2,570.00
Day Range2,490.00 – 2,600.00
52-Week Range2,250.00 – 7,010.00
Volume56.57K
Market Cap88.81B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield2.98%
Beta0.09
50-Day Avg2,734.10
200-Day Avg3,282.70

About

iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Seong-Jun Yoon
  • Employees73
  • HeadquartersThespia 5th floor, 701-704, Seongnam-si, South Korea, Korea
  • Websitehttps://www.intron.co.kr

Leadership

  • Mr. Seong-Jun YoonCEO, President & Inside Director · b. 1969
  • Mr. Kyung Won YoonCEO, VP of Planning & Management & Inside Director · b. 1971

Financials

Income Statement

Currency: KRW2012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.17B11.84B10.22B10.96B20.58B8.35B45.43B29.31B14.01B9.59B6.42B5.74B
Growth (%)-+44.78%-13.63%+7.24%+87.77%-59.45%+444.28%-35.49%-52.21%-31.57%-33.05%-10.56%
Cost of Revenue4.64B4.03B5.19B5.93B5.42B4.55B18.90B7.54B4.35B3.74B2.68B2.64B
Gross Profit3.53B7.80B5.03B5.03B15.17B3.80B26.53B21.77B9.66B5.84B3.74B3.10B
Gross Margin43.19%65.95%49.21%45.91%73.68%45.52%58.40%74.29%68.95%60.96%58.23%54.09%
Operating Expense4.65B5.92B6.20B11.41B10.00B8.05B10.66B11.69B11.13B14.88B8.97B11.01B
Operating Income-1.12B1.88B-1.17B-6.37B5.17B-4.25B15.87B10.08B-1.47B-9.04B-5.24B-7.90B
Operating Margin-13.64%15.93%-11.44%-58.13%25.10%-50.87%34.94%34.39%-10.52%-94.26%-81.61%-137.69%
EBITDA--------13.39B-6.01B-956.88M-7.00B
EBITDA Margin--------95.61%-62.66%-14.91%-121.90%
Net Income-1.18B1.56B-610.38M-8.73B8.71B-3.19B14.95B9.73B5.71B-9.70B-2.59B-8.96B
Net Income Margin-14.49%13.16%-5.97%-79.67%42.32%-38.18%32.90%33.19%40.78%-101.15%-40.37%-156.06%
R&D428.34M428.34M3.11B3.50B3.66B2.25B3.49B3.55B3.31B3.17B3.48B4.65B
R&D as % of Total Revenue5.24%3.62%30.38%31.93%17.78%26.98%7.68%12.12%23.65%33.11%54.20%81.09%
Interest Expense000001.22B1.18B1.64B3.51B2.92B23.41M89.93M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%14.56%2.61%5.58%25.03%30.45%0.36%1.57%

Balance Sheet

Currency: KRW2012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets19.64B40.37B59.61B45.63B54.80B89.03B100.54B153.37B140.96B98.61B86.37B74.32B
Total Liabilities7.72B5.93B10.46B15.38B15.70B24.07B15.16B52.02B34.78B1.88B2.60B4.45B
Total Equity11.93B34.44B49.15B30.24B39.09B64.96B85.38B101.35B106.18B96.73B83.77B69.87B
Cash3.03B9.60B19.27B15.75B21.12B53.33B59.92B2.93M2.27M40.99B34.36B27.66B
Total Debt--2.55B3.55B3.22B14.77B174.27M-----

Cash Flow

Currency: KRW2012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-331.01M1.70B-4.64B-5.47B4.20B-812.48M7.13B16.47B5.98B3.12B-138.47M-5.21B
Investing Cash Flow1.29B-3.71B-7.55B-1.96B-1.26B-4.52B2.36B-41.28B-46.22B52.15B3.07B-
Financing Cash Flow937.75M3.78B21.96B4.45B1.98B37.32B-2.07B39.75B-9.19B-40.17B-9.82B-
Capital Expenditure491.61M6.30B4.72B973.91M550.58M300.38M4.85B3.05B2.23B9.55B1.19B2.47B
Free Cash Flow------3.68B1.06B12.98B3.36B-6.43B-1.32B-7.68B
Dividends Paid----------3.32B3.20B
FCF to OCF-----453.09%14.87%78.79%56.22%-206.38%956.76%147.42%
Dividend Paid to FCF-----------250.53%-41.65%

Earnings

Report DateMar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015May 16, 2016Aug 16, 2016Nov 14, 2016Feb 24, 2017May 30, 2017Aug 29, 2017Nov 29, 2017Feb 28, 2018May 30, 2018Aug 16, 2018Nov 29, 2018Mar 27, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Mar 26, 2020May 15, 2020Aug 14, 2020Nov 13, 2020Mar 17, 2021May 14, 2021Aug 13, 2021Nov 12, 2021Feb 9, 2022May 13, 2022Aug 16, 2022Nov 14, 2022Feb 17, 2023May 15, 2023Aug 11, 2023Nov 14, 2023Mar 13, 2024May 14, 2024Aug 14, 2024Nov 12, 2024Mar 11, 2025May 15, 2025Aug 29, 2025Nov 12, 2025Mar 9, 2026May 14, 2026Aug 17, 2026
EPS Estimate------------------------------------13.42-20.36-8.3392.620.55---23.91-23.91-23.9116.5623.42---23.4223.4223.42---------
EPS Actual-1.91-7.4713.948.35-3.48-26.74-12.38-7.708.131.231.352.175.6711.8812.42-29.296.592.392.7140.81-5.88-6.45-12.174.507.98-106.0910.39-181.76-46.4765.46-145.67349.1511.8811.21-91.96-113.00-19.00291.0057.1672.0039.0099.0065.0073.19-36.00357.00-50.00-106.08-46.80-55.66-49.67-49.67-49.6717.46-39.82-45.08-59.85-32.72-52.59-135.28-72.53-72.38
Surprise------------------------------------742.03%6.68%3593.40%-38.29%12990.91%--371.85%406.11%-50.56%2055.80%-313.49%----312.08%-312.08%-312.08%---------
Timing--------------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap88.81B
Enterprise Value55.43B
Trailing P/E0.00
Forward P/E0.00
Price / Sales15.47
Price / Book1.40
Revenue (TTM)5.74B
Gross Profit (TTM)3.04B
EBITDA-5.96B
Profit Margin-156.06%
Operating Margin-119.82%
Return on Equity-11.66%
Return on Assets-6.15%
Shares Outstanding30.89M
Shares Float25.63M
Beta0.09
Dividend Yield2.98%
Dividend Rate100.00
Payout Ratio0.00%

Dividends

20251×
100.00Dec 29, 2025
20241×
100.00Dec 27, 2024
20231×
100.00Dec 27, 2023

Stock Splits

  • Jan 10, 20192:1
  • Oct 8, 201313:10